Two MUC1 peptides, a 30 aa and a 33 aa covalently conjugated to KLH and administered with QS-21 as immunological adjuvant, were tested in two phase I clinical trial in, respectively, nine and 10 breast cancer patients with no evidence of disease (NED) after treatment of a recurrence, elevated CEA or CA 15.3 levels or initially unresectable stage III disease post therapy. This evidence concerns the gene MUC1 and breast carcinoma.